Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Pharmacology

Background:

• Advanced-stage lymphoblastic lymphoma (LBL) in children requires effective treatment protocols.
• The Berlin-Frankfurt-Munster (BFM)-95 protocol is a standard treatment, but L-asparaginase can cause adverse events.
• Pegaspargase offers a potential alternative with a longer half-life and potentially different toxicity profile.

Purpose of the Study:

• To assess the feasibility and outcomes of substituting Pegaspargase for L-asparaginase in the BFM-95 protocol for pediatric LBL.
• To compare treatment response, survival rates, and complication profiles between the standard and modified BFM-95 protocols.

Main Methods:

• A cohort of 54 newly diagnosed pediatric patients with stage III or IV LBL were enrolled.
• Patients received either the standard BFM-95 protocol or a modified version using Pegaspargase.
• Treatment responses and complications were evaluated for both groups.

Main Results:

• Similar complete response rates, event-free survival, and overall survival were observed in both treatment groups.
• Myelosuppression was the most frequent complication in both protocols.
• The modified protocol showed a decrease in anaphylactic reactions but an increase in manageable coagulation defects.

Conclusions:

• The modified BFM-95 protocol with Pegaspargase is a viable option for advanced LBL in children.
• This modification maintains treatment efficacy while improving patient compliance and reducing anaphylaxis incidence.
• Coagulation defects are the primary complication in the modified protocol but are considered tolerable.